RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Trial Profile

RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Retinopathy of prematurity
  • Focus Therapeutic Use
  • Acronyms RainbowExt
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2017 Planned End Date changed from 1 Sep 2022 to 30 Oct 2022.
    • 12 Oct 2017 Planned primary completion date changed from 1 Sep 2022 to 30 Oct 2022.
    • 01 Apr 2017 The trial has been completed in Greece.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top